ҽ ҽԺ ֢״Բ ҩƷͨ Ӧ
ҳ > Ƥ > Ƥ > ״ > ״ >

ʹʹʹʹʹ...״ʹôΣһĶ

ٱ/
2022-01-05 14:53:49÷˹ҽѧ
ʾ״ʹpostherpeticneuralgiaPHNĴ״Բ֢ҲĸȾʹ͡

״ɳDZڼ񾭽ڻ­񾭽ڵˮ-״varicella-zoster virusVZVټĸȾƤ[1]òƤ⣬񾭲ʹϴƻȱݵȺУӰ컼ҲڿƵij

״ʹpostherpetic neuralgia PHNĴ״Բ֢ҲĸȾʹͨ͡PHNΪƤֺٳ1»3¡6µʹĿǰδɹʶõĶ弴״Ƥֺٳ3µʹ[2]ҹ״ʹйרƹʶȷָPHNƤϺ1¼ϵʹ[3]

PHNռ״ߵ5% ~ 30%ҹԼ400PHNߡPHNڸ䡢߹ܵ»ߣʹλͨ󣬳ڵز񾭻򾱲ʹʶΪ˺һʹΪʹ档һߵ˯ߡӰ칤ճؿɵ¾ϰ30% ~ 50%Ļʹ1ֲ꣬̿ɴ10[1]

ôPHNܳôԲͬ׶εĻ߽ƣ

ܵ˵PHNӦơۺƣҪЧ밲ȫԷգͬʱСʼӼΪԭ򡣴⣬ĿǸʹ˯ߡݡ״йרҹʶ2018 ꣩[1]ڴ˽飺

1.ҩ

ԸΪҺδʱ¯ʯϴΤΤࣻ3%Һ15 000߻Һʪ󣬻0.5%ù2%Īƥȡ۲3%Τ۸ࡢգҺƤʼƼ

2.ҩ

жʹǴӡ࿹ҩࣻضʹʹðƬҩȻǿͪ񾭲ʹҩͨڼӰ綡ֵȣҩ÷1

У״ڼضȼʹǷPHNΣأϸͨڼЧʹܼPHNоʾʹֿʹ״ʹ֣7 dʹPHNʡ

⣬ǿͪܽһPHNʣɸƻճ˯ߣ࿹ҩTCAs簢֣о5-ɫȥȡƼSNRIs͡ 5-ɫȥصȡ PHNܸľʹʹ׹ʹȣҲܸ˯ߡ

ͨЧΪ150-225 mg/dÿ1Ρ͡ļΪÿ30-60mg/dÿ1-2ΡӦע߳ӦжġڸɡǡӳѪյȡǿͪڵİƬҩȡǿ̫ͪᡢȣضPHNѡҩЧ PHN ʹʹʹСʼЧӦͣҩһʹò8ܡ

ͨʼÿ25-50 mgÿ1-2 Σ 400 mg/dҩͼʼ𽥼ͣҩҩҪIJӦġŻ¡ءͷΡ˯ͷʹȣء 5-ɫҩ SNRIsͬãԱ5-ɫۺա

3.Ԥ

ĿǰΨһȷ֤ݵԤ״ʹķԤ״ķУҩƼԴ״ɰοٴʾҩܽͼʹǿȡ֢״ʧʹʱ䡣

⣬оʾһִ״ZostavaxԤ60ȺPHNЧΪ66.5%[4]

ϣPHNһɷεļڼʱԤPHNʹ̶ȼصĿɿѡúʵҩƿЧPHNɸƻճ˯ߣ

οף

[1]״йרҹʶ[J].лƤ־201851(6)403-406

[2] PraudEUhartMB?hmK et al. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany[J]. Hum Vaccin Immunother 2015114884-896. doi 10.1080/21645515.2015.1011561.

[3]״ʹƹʶдר.״ʹйרҹʶ[J].йʹҽѧ־ 2016223161-167. doi 10.3969/j.issn.1006-9852.2016.03.001.

[4] PellissierJMBrissonMLevinMJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults[J]. Vaccine200725498326-8337. doi 10.1016/j.vaccine.2007.09.066.

39רҵҽƱϢƽ̨ ʽѶŻվ    

йȵĽŻվйǿ200039տͨйʷƾáģӵзḻӴûĽƽ̨ڽѶҽʴ𡢾ҽҩϢѯȷȣ߽Ϣ¶ȸdz4û

ر߻
Ƶ
֪޸ܽף 2019-05-15
㻹ڳԣʹ̫׾ 2019-04-29
нʲôʱԤã 2019-04-12
ᷢչΪٰ 2019-04-12
ٱ/
ӵַ*
ٱ⣺*ѡٱ
ԭӣ
ɣ
⼰飺
ϵʽ